Shane Schaffer Male • United States of America

Shane Schaffer, a seasoned leader with 25 years of experience, holds the titles of Co-founder, Chairman, and Chief Executive Officer at Cingulate Therapeutics, based in Kansas City, Kansas. This Phase 3 clinical-stage biopharmaceutical company is pioneering in the development of branded, next-generation pharmaceutical products, with a strong focus on Attention Deficit/Hyperactivity Disorders (ADHD) and extending into areas such as anxiety disorders and insomnia.



His professional journey is distinguished by a deep specialization in drug development and commercialization. He demonstrates his capacity through thoughtful leadership and a robust entrepreneurial spirit in various business operations, including product launches, brand planning, and market development.



He completed his doctoral degree in Pharmacy at the University of Kansas in 1999 and enhanced his expertise with a postdoctoral fellowship at Rutgers University's College of Pharmacy. He contributed significantly to Pfizer Worldwide Marketing and Morris Plains during his fellowship. At Pfizer Worldwide Marketing in New York, he served as a Marketing Manager, where he was instrumental in developing pre-launch strategies and initiating a Global Communications Intranet to foster better communication between medical and marketing teams.



In Morris Plains, New Jersey, he assumed the roles of Project Manager and External Research Manager, enhancing sales training and overseeing Phase IV Medical Research across all marketed brands. This role underpinned his capability in both leadership and operational management.



Throughout his illustrious career, he has held several managerial positions at Pfizer, Novartis, and Sanofi, contributing to developing and commercializing several billion-dollar brands. At Novartis, he was pivotal in managing the Ritalin® LA and Focalin™ segments, significantly enhancing product awareness and market penetration, achievements that earned him multiple prestigious awards.



His tenure at Sanofi Aventis demonstrated his dynamic professional personality, particularly during the company's merger and joint venture phases. He played a key role in the professional promotion and sales force execution for Avapro and Avalide, spearheading promotional campaigns and recruitment efforts.



Following his time at Sanofi-Aventis, he joined M|C Communications in Boston as a Consultant, leading the development of business strategies for over a dozen major pharmaceutical firms. In 2009, he founded Sabre Scientific Solutions, LLC, providing vital consulting services for pharmaceutical and biotechnology companies' commercial, clinical, and leadership aspects.



In January 2013, driven by his passion for addressing ADHD and related disorders, he established Cingulate Therapeutics. His vision for the company focuses on innovating drug delivery technologies to improve treatment efficacy and patient independence from continuous medication. Cingulate has recently partnered with Indegene to market CTx-1301, an oral ADHD medication now in Phase 3 trials, with plans to submit a new drug application to the FDA by mid-2025.



Beyond his corporate achievements, Shane Schaffer is actively involved in philanthropy, particularly with Folds of Honor Charity, which provides educational scholarships to children affected by the loss or disability of military personnel, reflecting his commitment to making a significant impact beyond the pharmaceutical industry.